ReviewBone research2017
Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis.
Review in Bone research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 202 citations in OpenAlex.
- Effect of Fermented Soymilk-Honey from Different Probiotics on Osteocalcin Level in Menopausal Women.Nutrients · 2021Trial
- Trial
- Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial.Diabetes care · 2019Trial
- Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota.Scientific reports · 2018Trial
- Amuc_1473 Links Gut Microbes to Skeletal Homeostasis and Counteracts Multifactorial Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Plant Transformation States and Exposure Architecture: A Pharmacokinetic Framework for Plant-Derived Compounds in Bone Remodeling.Plants (Basel, Switzerland) · 2026Review
- Article
- Benefits that Death Does Not Part: the Promise of Postbiotics for Bone Health.Probiotics and antimicrobial proteins · 2026Review
- Aging-Driven Inter-Organ Crosstalk in Postmenopausal Osteoporosis: From Immunometabolic Drift to Multisystem Frailty.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Role of the gut microbiota in the pathogenesis and therapeutic approach to osteoporosis (Review).Biomedical reports · 2026Review
- Gut microbiota orchestrates bone homeostasis: a multi-pathway network from intestine to skeleton.Frontiers in endocrinology · 2026Review
- Article
- Sijing Pill modulates PGE2/EP4/PI3K-AKT pathway via gut-bone axis to treat postmenopausal osteoporosis.Frontiers in microbiology · 2026Article
- The gut-bone axis: potential influence of anthocyanins and implications for postmenopausal osteoporosis.Food science and biotechnology · 2026Review
- Gut microbiota-derived TMAO drives the kidney-bone-vascular axis in chronic kidney disease complications.Renal failure · 2025Review
- 2'-Fucosyllactose ameliorates aging-related osteoporosis by restoring gut microbial and innate immune homeostasis.Journal of advanced research · 2025Article
- Dietary fiber derived short-chain fatty acids as a critical driver of the gut-bone axis in animal bone health: A review.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025Review
- Beyond Bone Loss: A Biology Perspective on Osteoporosis Pathogenesis, Multi-Omics Approaches, and Interconnected Mechanisms.Biomedicines · 2025Review
- Progress of research on the gut microbiome and its metabolite short-chain fatty acids in postmenopausal osteoporosis: a literature review.Frontiers of medicine · 2025Review
- Dysregulation of miR-106a-5p/PTEN axis associated with progression and diagnostic of postmenopausal osteoporosis.Journal of orthopaedic surgery and research · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease characterized by bone loss and structural destruction, which increases the risk of fracture in postmenopausal women. Owing to the high morbidity and serious complications of PMO, many efforts have been devoted to its prophylaxis and treatment. The intestinal microbiota is the complex community of microorganisms colonizing the gastrointestinal tract. Probiotics, which are dietary or medical supplements consisting of beneficial intestinal bacteria, work in concert with endogenous intestinal microorganisms to maintain host health. Recent studies have revealed that bone loss in PMO is closely related to host immunity, which is influenced by the intestinal microbiota. The curative effects of probiotics on metabolic bone diseases have also been demonstrated. The effects of the intestinal microbiota on bone metabolism suggest a promising target for PMO management. This review seeks to summarize the critical effects of the intestinal microbiota and probiotics on PMO, with a focus on the molecular mechanisms underlying the pathogenic relationship between bacteria and host, and to define the possible treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.